Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 12
Submit an article Journal homepage
134
Views
74
CrossRef citations to date
0
Altmetric
Research Article

Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies

Giovanni Barosi Laboratorio di Informatica Medica, IRCCS Policlinico S. Matteo, 27100 Pavia, Italy
,
Michelle Elliott Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
,
Letizia Canepa Department of Hematology and Oncology, Azienda Ospedaliera San Martino, Genova, Italy
,
Filippo Ballerini Department of Hematology and Oncology, Azienda Ospedaliera San Martino, Genova, Italy
,
Pier Paolo Piccaluga Institute of Hematology and Clinical Oncology “L.&A. Seragnoli”, University of Bologna, Bologna, Italy
,
Giuseppe Visani Department of Hematology, San Salvatore Hospital, Pesaro, Italy
,
Monia Marchetti Laboratorio di Informatica Medica, IRCCS Policlinico S. Matteo, 27100 Pavia, Italy
,
Gabriele Pozzato Unità Clinico Operativa Medicina Clinica, Ospedale di Cattinara, 34100 Trieste, Italy
,
Francesca Zorat Unità Clinico Operativa Medicina Clinica, Ospedale di Cattinara, 34100 Trieste, Italy
&
Ayalew Tefferi Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
 show all
Pages 2301-2307 | Published online: 01 Jul 2009

  • Barosi, G, (1999) "Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines", Journal of Clinical Oncology 17, 2954-2970.
  • Teffferi, A. (2000) "Myeloofibrosis with myeloid metaplasia", New England Journal of medicine 342, 1255-1265.
  • Visani, G., Finelli, C., Castelli, U., Petti, M.C., Ricci, P., Vianelli, N., Gianni, L., Zuffa, E., Aloe Spiriti, M.A., Latagliata, R., Pileri, S., Magrini, U., Gugliotta, L., Morra, E., Bernasconi, C., Mandelli, F. and Tura, S. (1990) "Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients". British Journal of Haematology 75, 4-9.
  • Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. and Bauters, F, (1996) "Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system", Blood 88, 1013-1018.
  • Barosi, G., Grossi, A., Comotti, B., Musto, P., Gamba, G, and Marchetti, M. (2001) "Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia". Haematologica 86, 772-773.
  • Canepa, L., Ballerini, F., Varaldo, R., Quintino, S., Reni, L., Clavio, M., Miglino, M., Pierri, I. and Gobbi, M. (2001) "Thalidomide in agnogenic and secondary myelofibrosis", British Journal of Haematnhgv 115, 313-315.
  • Puuzato, G., Zorat, F., Nascimben, F., Comar, C., Kikie, F. and Festini, G. (2001) "Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia", Haematologia 86, 172-773.
  • Elliott, M.A., Mesa, R.A., Li, C.Y., Hook, C.C., Ansell, S.M., Livitt, R.M., Geyer, S.M. and Tefferi, A. (2002) "Thalidomide treatment in myelofibrosis with myeloid metaplasia", British Journal of Haematology 117, 288-296.
  • Piccaluga, P.P., Visani, G., Pileri, S.A., Ascani, S., Grafone, T., Isidori, A., Malagola, M., Finelli, C., Ricci, P., Baccarani, M. and Tura, S. (2002) "Clinical efficacy and antiangiogenetic activity of thalidomide in myelofibrosis with myeloid metaplasia. a pilot study". Leukemia and Lymphoma, In press.
  • Tefferi, A. and Elliot, M.A. (2000) "Serious mycloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia". Blood 96, 4007.
  • Mesa, R.A., Hanson, C.A., Rajkumar, S.V., Schroeder, G. and Tefferi, A. (2000) "Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia". Blood 96, 3374-3380.
  • Singhal, S., Metha, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Barlogie, B., Siegel, D. and Crowiey, J. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New England Journal of Medicine 341, 1565-1571.
  • Yakoub-Agha, I., Moreau, H. Leyvraz, S., Berthou, C., Payen, C., Dumontet, C., Grosbois, B., Beris, P., Duguet, C., Attai, M., Harousseau, J.L. and Facon, T, (2000) "Thalidomide in patients with advanced multiple myeloma", The Hematology Journal 1, 186-189.
  • Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C. Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P. and Zeldis, J. (2001) "Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes". Blood 98, 958-965.
  • Kvasnicka, H.M. and Thiele, J. (2000) "Apoptosis and proliferation in the bone marrow of chronic myeloproliferative disorders-biological and prognostic importance". Pathologe 21, 55-62.
  • Zurat, F., Shetty, V. Dutt, D., Lisak, L., Naseimben, F., Allampallam, K., Dar, S., York, A., Gezer, S., Venugopal, P. and Raza, A. (2001) "The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes", British Journal of Haematology 115, 881-894.
  • MilMades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. and Anderson, K.C. (2002) "Apoptotic signaling induced by immuno-modulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications", Blood 99, 4525-4530.
  • Singhal, S. and Mehta, J. (2002) "Thalidomide in cancer", Biomedical Pharmacotherapy 56, 4-12.
  • Wohl, D.A., Aweeka, E.T., Schmitz, J., Pomerantz, R., Cherng, D.W., Spritzler, J., Fox, L., Simpson, D., Bell, D., Holohan, M.K., Thomas, S., Robinson, W., Kaplan, G. and Teppler, H. (2002) "Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267", Jouranl of Infections Diseases 185, 1359-1363.
  • Steins, M.B., Padro, T., Bieker, R., Ruiz, S., Kropff, M., Kienasy, J., Kessler, T., Buechner, T., Berdel, W.E. and Mesters, R.M. (2002) "Efficacy and safety of thalidomide in patients with acute myeloid leukemia", Blood 99, 834-839.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.